2023
DOI: 10.1016/j.intimp.2022.109551
|View full text |Cite
|
Sign up to set email alerts
|

Enhanced anti-biofilm activity of the minocycline-and-gallium-nitrate using niosome wrapping against Acinetobacter baumannii in C57/BL6 mouse pneumonia model

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 60 publications
0
2
0
Order By: Relevance
“…Shamkani et al loaded minocycline and gallium nitrate into niosomes and validated the anti-biofilm activity toward Acinetobacter baumannii . 197 In order to form an aqueous polymer solution, polyethylene glycol and polyvinylpyrrolidone were incorporated into the as-prepared niosomal formulation. Entrapment efficiencies for gallium nitrate and minocycline niosomal formulations were 42.5 and 81.5%, respectively.…”
Section: Treatment Of Infectionsmentioning
confidence: 99%
“…Shamkani et al loaded minocycline and gallium nitrate into niosomes and validated the anti-biofilm activity toward Acinetobacter baumannii . 197 In order to form an aqueous polymer solution, polyethylene glycol and polyvinylpyrrolidone were incorporated into the as-prepared niosomal formulation. Entrapment efficiencies for gallium nitrate and minocycline niosomal formulations were 42.5 and 81.5%, respectively.…”
Section: Treatment Of Infectionsmentioning
confidence: 99%
“…[29][30][31] In particular, as an FDA approved drug, the antibacterial mechanism, effect, and application of gallium nitrate have been extensively studied. [32][33][34][35] Although there have been many studies on antibacterial MOFs, few studies on gallium-based MOFs have been reported. 36 In this study, we synthesized a Ga-based MOF as a platform to load melittin (MEL), a typical AMP stemmed from honeybee (Apis mellifera) venom, and investigated its antibacterial activity against clinical isolated methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli (E. coli).…”
Section: Introductionmentioning
confidence: 99%